University of Greifswald   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Greifswald Germany (1456)

Organization Overview

First Clinical Trial
1999
NCT01429090
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Clinic and Polyclinic of Dermatology, University of Greifswald | Klinik und Poliklinik für Innere Medizin C, Hämatologie und Onkologie, Transplantationszentrum, Universitätsmedizin Greifswald | Prof. F. Heidel, University Medicine Greifswald | The Department of Preventive and Pediatric Dentistry, University of Greifswald | Universitätmedizin Greifswald | University Greifswald | University Hospital Greifswald | University Medicine Greifswald | University Medicine Greifswald, Institute CM, Department of Prevention Research and Social Medicine | University Medicine Greifswald, Institute for Medical Psychology | University Medicine Greifswald, Institute of Medical Psychology | University Medicine of Greifswald | University of Greifswald

Active Ingredients

Drugs in Phase 4 Trials (5)

colchicine (colbenemid) (1 trial)

heparin (liquaemin) (2 trials)

icosapent ethyl (vascepa) (1 trial)

povidone-iodine (betadine) (1 trial)

prednisolone (hydeltra) (1 trial)

Drugs in Phase 3 Trials (12)

beta carotene (solatene) (1 trial)

betamethasone (celestone) (1 trial)

levocarnitine (carnitor) (1 trial)

magnesium oxide (1 trial)

magnesium sulfate (Tis-U-Sol) (1 trial)

potassium iodide (thyro-block) (1 trial)

selenium (1 trial)

silver fluoride (1 trial)

sodium fluoride (18F) (1 trial)

spironolactone (aldactone) (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Drugs in Phase 2 Trials (11)

aldesleukin (Proleukin) (1 trial)

dinutuximab (unituxin) (3 trials)

epirubicin (ellence) (1 trial)

fedratinib (Inrebic) (1 trial)

gadoxetate disodium (eovist) (1 trial)

gemcitabine (gemzar) (1 trial)

isotretinoin (Accutane) (1 trial)

midazolam (versed) (1 trial)

nivolumab (opdivo) (3 trials)

pazopanib (votrient) (1 trial)

trabectedin (yondelis) (1 trial)

Drugs in Phase 1 Trials (25)

acetaminophen (tylenol) (3 trials)

clarithromycin (biaxin) (1 trial)

dapsone (aczone) (1 trial)

efavirenz (sustiva) (1 trial)

ergoline (1 trial)

ezetimibe (zetia) (3 trials)

fexofenadine (allegra) (1 trial)

Flupirtine (katadolon) (1 trial)

grapefruit juice (1 trial)

ketamine (ketalar) (1 trial)

leukocytes (1 trial)

loperamide (imodium) (2 trials)

methantheline bromide (banthine) (1 trial)

methylnaltrexone (relistor) (2 trials)

naloxone (narcan) (1 trial)

procaine benzylpenicillin (novocaine) (2 trials)

propranolol (inderal) (2 trials)

ranitidine (zantac) (1 trial)

rifampin (1 trial)

sirolimus (rapamune) (1 trial)

sulfasalazine (azulfidine) (3 trials)

tacrolimus (prograf) (1 trial)

talinolol (2 trials)

trospium (sanctura) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Other Trials (3)

berberine (2 trials)

thiamine (1 trial)

wheat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinosarcoma (Phase 2)

Delayed Emergence from Anesthesia (Phase 2)

Endophthalmitis (Phase 4)

Hemorrhage (Phase 4)

Hypercholesterolemia (Phase 1)

Intestinal Obstruction (Phase 1)

Leiomyosarcoma (Phase 2)

Linear IgA Bullous Dermatosis (Phase 1)

Methemoglobinemia (Phase 1)

Mixed Tumor, Mullerian (Phase 2)

Neuroblastoma (Phase 2)

Neurodermatitis (Phase 3)

Obesity, Morbid (Phase 1)

Pancreatic Neoplasms (Phase 3)

Pancreatitis (Phase 3)

Sarcoma (Phase 2)

Sepsis (Phase 4)

Skin Diseases (Phase 1)

Skin Diseases, Vesiculobullous (Phase 1)

Strabismus (Phase 4)

Systemic Inflammatory Response Syndrome (Phase 4)

Thrombocytopenia (Phase 4)

Toxemia (Phase 4)

Urinary Bladder, Neurogenic (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 40
  • # of Trial APIs: 56